These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [pH gradient support and antacid action of gastroesophageal coating agents. In vitro pharmacologic study using a model of "the artificial stomach"]. Vatier J; Vitre MT; Vallot T; Mignon M Gastroenterol Clin Biol; 1990; 14(5):414-22. PubMed ID: 2163935 [TBL] [Abstract][Full Text] [Related]
4. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux. Ward AE Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176 [No Abstract] [Full Text] [Related]
5. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects]. Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860 [No Abstract] [Full Text] [Related]
6. Algicon in the management of gastro-oesophageal reflux. Lambert JR; Korman MG; Nicholson L Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177 [No Abstract] [Full Text] [Related]
7. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. Malmud LS; Charkes ND; Littlefield J; Reilley J; Stern H; Rosenberg R; Fisher RS J Nucl Med; 1979 Oct; 20(10):1023-8. PubMed ID: 231639 [TBL] [Abstract][Full Text] [Related]
8. [Bioavailability of orally administered iron. Effects of alginate/antacid administration]. Campo S; Breda E Minerva Med; 1992 Mar; 83(3):145-7. PubMed ID: 1553063 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension]. Guerre J; Neuman M; Bouchet J Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126 [No Abstract] [Full Text] [Related]
12. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension. Washington N; Greaves JL; Iftikhar SY Aliment Pharmacol Ther; 1992 Oct; 6(5):579-88. PubMed ID: 1420749 [TBL] [Abstract][Full Text] [Related]
13. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Mandel KG; Daggy BP; Brodie DA; Jacoby HI Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650 [TBL] [Abstract][Full Text] [Related]
15. [Chemico-physical property and bile acid binding capacity of several antacids]. Salvioli G; Tambara E; Gaetti E; Lugli R Minerva Dietol Gastroenterol; 1989; 35(2):79-83. PubMed ID: 2548124 [TBL] [Abstract][Full Text] [Related]
16. [Effect of antacids on mineral metabolism in persons with healthy kidneys. Double-blind study using an antacid containing magnesium aluminum silicate hydrate]. Herzog P; Holtermüller KH MMW Munch Med Wochenschr; 1982 Oct; 124(42):921-3. PubMed ID: 6298611 [No Abstract] [Full Text] [Related]
17. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy. Lang GD; Dougall A Br J Clin Pract Suppl; 1989 Feb; 66():48-51; discussion 61-4. PubMed ID: 2556175 [No Abstract] [Full Text] [Related]
18. The mode of action and complications of Infant Gaviscon. Keipert JA Aust Paediatr J; 1979 Dec; 15(4):263-5. PubMed ID: 44677 [No Abstract] [Full Text] [Related]
19. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension]. Chevrel B Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459 [No Abstract] [Full Text] [Related]